Anemia Treatment Market is expected to reach USD 14.9 Billion by 2028, Rising at a 6.9% CAGR | FMI Study

Anemia, a condition characterized by a lack of red blood cells, is gaining significant attention, impacting the global treatment market. According to a recent analysis, the Anemia Treatment Market is experiencing a surge, surpassing a value of USD 10.0 billion in 2022. This positive trend is expected to continue, with projections indicating a robust expansion to a staggering USD 14.9 billion by 2028. This translates to a remarkable CAGR (Compound Annual Growth Rate) of 6.9%, reflecting the growing need for effective anemia treatments.

According to a recent report released by Future Market Insights, a significant portion of the demand for Anemia therapy can be attributed to cases arising from one or more chronic medical conditions. This underscores the critical role the industry plays in addressing the healthcare needs of individuals facing anemia associated with various chronic ailments.

The demand for Anemia treatment is chiefly driven by chronic kidney disease (CKD), one of the non-communicable chronic diseases contributing to the demographic shift in emerging regions. Additionally, the increasing popularity of combination therapy is poised to make a substantial impact on the Global Anemia Treatment Industry. The growing utilization of antibiotics, metal chelating agents, erythropoietin-stimulating drugs, and vitamin and iron supplements in combination therapy is recognized as a key driver elevating the prospects of the Anemia treatment Industry in the years to come.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-8966

Vitamin Supplements Gain Significant Traction for Anemia Treatment

A surge in R&D investments is prominently improving the scope of anemia treatment. Moreover, a rising number of pipeline drugs and the promising potential of biosimilars will contribute to the demand for anemia treatment. However, the high price point associated with biologics continues to mask their superior treatment efficacy over conventional medications.

More than 75% of anemia treatment Industry revenue is accounted by medications, of which, ESAs (erythropoietin stimulating agents) remain bestselling. Blood transfusion is also cited as an important type of anemia treatment, contributing to the market growth. However, the demand for the former is poised for a robust double-digit yearly growth in 2021 and ahead.

The lucrative emergence of ESAs and soaring consumption of other biosimilar medications are likely to introduce new investment opportunities in the Global Anemia Treatment Industry. The extensive availability, accessibility, and economic price point of biosimilar drugs are strongly backed by an increasing number of FDA approvals. This according to FMI will significantly contribute to the improvement of CKD, thereby bolstering the revenue of the anemia treatment Industry. FDA recently issued approval to a biosimilar drug by Pfizer for use in anemia treatment – Retacrit (epoetin alfa-epoxy). Over 55% of dietary supplements consumed as a part of anemia treatment are vitamin supplements. An increasing number of iron-deficient patients will

reportedly result in rapid demand growth for iron supplements in years to come, posing strong competition to those vitamin supplements in the Global Anemia Treatment Industry. Currently, almost 60% of the medications and dietary supplements for anemia treatment are available at institutional pharmacies. The report also points to a gradually expanding share of retail pharmacies shortly.

North American patients raise just under a third of the global demand for anemia treatment, whereas more than a third of the total demand is accounted for collectively by East and South Asia. Europe is also cited as one of the key regional markets for anemia treatment providers.

Product-based Business Models Emerge as a Key Competitive Strategy

The consistent quest for therapeutically effective ESAs, dietary supplements, antibiotics, and other biologics to be used in anemia treatment continues to create attractive avenues in the R&D realm. Leading drug manufacturers are investing efforts in launching novel products and upgrading their existing consumable product portfolios. Amgen’s epoetin alpha has been a breakthrough product since its launch in the CKD treatment landscape and growing adoption continues to benefit the company.

Besides augmenting R&D investments, prominent players in the anemia treatment Industry are also focusing on strategic agreements and partnerships – further paving the way for the development of anemia treatment drugs. The emergence of partnership-based models in the competitive landscape of the anemia treatment market is likely to reshape the R&D structure in the anemia treatment Industry. The report prompts major investment opportunities arising in open collaboration strategies. Several drug manufacturers are also opting for partnerships with regional distribution leaders to form effective product-based distribution channels, particularly targeting developing regional markets.

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/8966

Anemia Treatment Market by Category

By Treatment:

• Medications
• Dietary Supplements

By Disease:

• Normocytic anemia
• Microcytic anemia
• Macrocytic anemia

By Distribution Channel:

• Institutional Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

Anemia Treatment Market Key Companies Profiled:

1. Amgen Inc.
2. Hoffmann-La Roche Ltd.
3. Novartis AG
4. Pfizer Inc.
5. Janssen Pharmaceuticals, Inc.
6. Teva Pharmaceutical Industries Ltd.
7. AMAG Pharmaceuticals
8. Rockwell Medical
9. Akebia Therapeutics
10. Vifor Pharma Management Ltd.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube